8 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
OncoTrack - Methods for systematic next generation oncology biomarker development (ONCOTRACK)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,
We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients with colon carcinoma, based on a combination of deep sequencing and chip based techniques. Dependent on their availability, we shall also perform analyses of tumor stem cells, circulating tumor cells, free tumor DNA in serum and xenografts derived from the same p ...
Voir le projet
22
Participants partenaires
TERMINÉ
A European Platform for Translational Cancer Research (EUROCANPLATFORM)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,
Europe has a number of advantages as regards developing translational cancer research, yet there is no clear European strategy to meet the increasing burden posed by cancer. The FP6 Eurocan+Plus project analysed the barriers underlying the increasing fragmentation of cancer research and stressed the need to improve collaboration between basic/preclinical and comprehensive cancer centres (CCCs), in ...
Voir le projet
29
Participants partenaires
TERMINÉ
Rational Therapy for Breast Cancer: Individualized Treatment for Difficult-to-Treat Breast Cancer Subtypes (RATHER)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,
"Cancer genotyping has identified a number of correlations between mutations in specific genes and responses to targeted anti-cancer drugs, with many mutations occurring in kinases or downstream signaling components. While there are several ongoing large-scale genome re-sequencing studies for the major cancer types, there is no systematic effort to investigate kinase mutations in distinct biologic ...
Voir le projet
8
Participants partenaires
TERMINÉ
WINTHERapeutics: development of a systems biology method to predict efficacy of cancer drugs to optimize individualized therapeutic decision and improve clinical outcome for cancer patients (WINTHER)
Date du début: 1 mars 2013, Date de fin: 28 févr. 2015,
Relevance: WINTHER project focuses on the development and validation, in 24 months, of industry supported new tools and computational methods, to predict efficacy of drugs in cancer patientsCurrent medical needs: Selection of cancer targeted therapies based on molecular abnormalities (mutations /amplifications/ translocations) benefit today only to 10-40% of patients. For the remaining majority, ...
Voir le projet
12
Participants partenaires
TERMINÉ
OVErcoming Resistance to anti-HER2 therapy (OVER-HER2)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2014,
"HER2 is a membrane receptor tyrosine kinase overexpressed in 30% of breast tumors and results in an aggressive clinical course. Anti-HER2 therapies including monoclonal antibodies (trastuzumab) and small-molecule tyrosine kinase inhibitors (lapatinib) are active and have improved survival of patients with HER2 overexpressing breast cancer. However, the emergence of primary or acquired resistance ...
Voir le projet
2
Participants partenaires
TERMINÉ
Modelling and predicting sensitivity to targeted therapies in colorectal cancers (COLTHERES)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2014,
Effective and long term treatment of cancer is now in sight, but will ultimately require an increasingly ‘personalised’ approach where the ‘right’ combination of drugs will be administered to the ‘right’ patients, based on a detailed understanding of their genetic background and their co-associated sensitivity or resistance ‘biomarkers’. Efforts are specifically required to identify validated risk ...
Voir le projet
11
Participants partenaires
TERMINÉ
Role of Notch signaling pathway in Glioma Stem Cells (Notch pathway in GSC)
Date du début: 1 juin 2012, Date de fin: 20 sept. 2014,
Glioblastoma multiforme (GBM) is the most common malignant intracranial tumor in adults. Despite the knowledge of the genetic alterations associated to GBM and the improvement in neurosurgery and chemo- and radiotherapy, little improvement has been achieved in the median survival. Recently, glioma stem cells (GSCs) have been identified to be responsible of the origin, recurrence and drug resistanc ...
Voir le projet
2
Participants partenaires
TERMINÉ
Targeting Cancer Stem Cells (CSC) for the development of more effective treatments to cure cancer patients (Anti-CSC)
Date du début: 1 déc. 2012, Date de fin: 30 nov. 2013,
Global cancer market is growing at a CAGR of 6.9% with an estimated value of $81bn in 2016. Although the huge R&D investment observed in the past years in the development of new treatments, there is still lack on an effective treatment in many tumour types. In particular, the median survival for glioblastoma multiforme (GBM), a high-grade brain tumour affecting 23,000 patients a year in US and EU, ...
Voir le projet